All evidence | Drugs and Technologies | Medicines and Healthcare products Regulatory Agency - MHRA, British National Formulary for Children - BNFc, Royal College of Psychiatrists - RCPsych, Brain Tumour Charity, Arthritis Research UK, Canadian Paediatric Society, British HIV Association - BHIVA, European Society of Gastrointestinal Endoscopy, NHS Improvement | Medicines Current Awareness | Search results page 1 | Evidence search

Add this result to my export selection

Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (updated)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021

A new version of this vaccine information for UK healthcare professionals includes (in Section 6.6) allowing for an additional dose to be taken if there is sufficient liquid left for a further full...

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Oxford University/AstraZeneca vaccine authorised by MHRA

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 30 December 2020

The JCVI has subsequently recommended that as many people on the priority list as possible should be offered a first vaccine dose as the initial priority (as opposed to prioritising completing the 2...

Read Summary

SPS comment

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

COVID-19 Vaccine Moderna authorised in the UK for temporary supply

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021

This is the third Covid-19 vaccine (the second mRNA vaccine) to have been given regulatory approval for supply by the MHRA. It is approved for use in people aged 18 years and requires two doses.

Read Summary

SPS comment

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021

The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if...

Read Summary

SPS comment

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Use of medicines in pregnancy and breastfeeding

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 January 2021

This guidance signposts patients, healthcare professionals and developers of new medicines to advice and resources on medicines in pregnancy and breastfeeding and is supported by Safer Medicines in...

Read Summary

SPS comment

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Covid-19 Therapeutic Alert: Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients - Trial Use Only

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 12 February 2021

Colchicine should NOT be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use. Although early...

Read Summary

SPS comment

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 09 December 2020

MHRA has advised that any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine; and a second dose should not be given to anyone who has...

Read Summary

SPS comment

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021

Data from observational studies suggest use of SSRI/SNRI antidepressants during month before delivery may result in small increased risk of postpartum haemorrhage. Prescribers should consider this...

Read Summary

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Medicines in pregnancy and breastfeeding: new initiative for consistent guidance; report on optimising data for medicines used during pregnancy

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

Information is provided on the newly launched Safer Medicines in Pregnancy and Breastfeeding Consortium and a new report provides recommendations on ways in which data on medicines used in pregnancy...

Read Summary

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Alkindi (hydrocortisone granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

Adrenal crisis has been reported in an infant switched from hydrocortisone soluble tablets to Alkindi. When children on replacement therapy for adrenal insufficiency (AI) are being switched, parents...

Read Summary

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Search results

Filter

Evidence type

Area of interest

Source

Filter by Date

59 results for All evidence

Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (updated)

Oxford University/AstraZeneca vaccine authorised by MHRA

COVID-19 Vaccine Moderna authorised in the UK for temporary supply

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

Use of medicines in pregnancy and breastfeeding

Covid-19 Therapeutic Alert: Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients - Trial Use Only

Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine

SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Medicines in pregnancy and breastfeeding: new initiative for consistent guidance; report on optimising data for medicines used during pregnancy

Alkindi (hydrocortisone granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules